Acadia Pharmaceuticals | ACAD - 销售和管理费用

金融业

USD

USD 1.56B

现金及等价物

USD 819.69M

USD 26.23M

USD 1.06B

USD 277.11M

USD 54.81M

USD 17.39M

USD 35.76M

653

EPS每股收益

USD 1.6

股本和储备

USD 917.27M

USD 257.76M

债务利息支出

USD 0

USD 8.25M

USD 0

USD 3.69B

USD 273.57M

USD 266.6M

USD 17.39M

普通股股本

USD 169.18M

11.61

USD 26.32M

USD 284M

销售和管理费用

USD 146.73M

USD 34.67M

贸易债权人

USD 10.9M

应收帐款人

USD 148.23M

	销售和管理费用	更改		日
Acadia Pharmaceuticals	USD 146.73M		21.82M	2025-12
ALKERMES	USD 187.2M		15.43M	2025-12
Alnylam Pharmaceuticals	USD 285.06M		22.47M	2025-12
Biogen	USD 545.2M		38.6M	2025-09
BioMarin Pharmaceutical	USD 322.21M		98.79M	2025-12
Bristol-Myers Squibb	USD 2.18B		392M	2025-12
Cara Therapeutics	USD 2.19M		2.45M	2025-09
Corcept Therapeutics	USD 114.74M		7.77M	2025-12
Cytokinetics	USD 91.72M		67.02M	2025-12
Eisai	JPY 111.72B		7.86B	2025-12
Eli Lilly	USD 3.13B		391.3M	2025-12
Incyte	USD 390.41M		61.33M	2025-12
J&J	USD 6.75B		831M	2025-12
Moderna	USD 308M		40M	2025-12
Neurocrine Biosciences	USD 301.8M		10.2M	2025-12
Pfizer	USD 4.08B		894M	2025-12
Prothena	USD 7.65M		5.59M	2025-12
PTC Therapeutics	USD 87.2M		3.15M	2025-12
Sarepta Therapeutics	USD 105.38M		28.27M	2025-12
Ultragenyx Pharmaceutical	USD 89M		2.38M	2025-12
Vanda Pharmaceuticals	USD 39.28M		1.71M	2024-12
Vertex Pharmaceuticals	USD 487M		41.9M	2025-12